Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target Amid Optimism for ML-007C-MA
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on MapLight Therapeutics with a $45 price target, citing optimism for ML-007C-MA's clinical profile. He highlights potential advantages in dosing and tolerability over Cobenfy, particularly if Phase 2 schizophrenia data shows efficacy. Needham also assigned a Buy rating with the same price target.
LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on MapLight Therapeutics, Inc. today and set a price target of $45.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Francois Brisebois has given his Buy rating due to a combination of factors tied to ML-007C-MA’s emerging clinical and commercial profile. Feedback from key psychiatry experts suggests that ML-007C-MA’s more convenient dosing regimen and potentially better tolerability could overcome important real-world limitations seen with Cobenfy, the first approved non-dopaminergic option.
Brisebois also sees meaningful upside if upcoming Phase 2 schizophrenia data show efficacy comparable to Cobenfy but with a clearer tolerability advantage, which KOLs believe could drive substantially higher long-term use. Combined with the sizable unmet need in both schizophrenia and Alzheimer’s psychosis, and the unchanged $45 price target, he views MapLight Therapeutics as positioned for favorable risk-reward and reiterates a positive stance on the stock.
In another report released on July 10, Needham also assigned a Buy rating to the stock with a $45.00 price target.